XLK News Alert Technology Select Sector SPDR (XLK) 41.67 11/18/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 11:06 PM

Technology Select Sector SPDR (XLK) 41.67 $XLK

Benedict Evans' Presentation At Bloomberg's The Year Ahead Event: Mobile Outlook (Video)
Benedict Evans - at Seeking Alpha - Mon Nov 17, 10:46AM CST
Last week Benedict Evans presented at Bloomberg's The Year Ahead event in Washington DC: video and slides below. Read comments Read more articles from Seeking Alpha: 5 Stocks To Watch This Week 11-17-14 Did Fox's 'Gone Girl' Just Give...
XLK: 41.67 (+0.14), VGT: 104.81 (+0.59)

Going Vertical
Bob O'Donnell - Seeking Alpha - Tue Nov 11, 5:13PM CST
The foundation of the tech business has nearly always been based on the idea of creating products and services that appeal to as wide an audience as possible. As we begin to enter a more mature, slower growth phase of the industry, however, the...
IBM: 161.89 (-2.27), XLK: 41.67 (+0.14), AAPL: 115.47 (+1.48)

U.S., China to liberalize tech trade
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 1:52AM CST

PXQ: 34.03 (+0.32), ROM: 152.49 (+1.68), TLL: 55.40 (unch), CQQQ: 37.01 (-0.56), XSW: 93.00 (+0.29), QTEC: 43.24 (+0.33), PBS: 25.05 (+0.13), PTF: 37.25 (+0.53), FXL: 33.68 (+0.38), IYZ: 30.59 (+0.01), TECL: 142.12 (+1.69), TDIV: 27.90 (+0.17), XLK: 41.67 (+0.14), XSD: 73.11 (+1.47), IYW: 104.57 (+0.55), XTL: 57.07 (+0.28), SOXS: 15.97 (-0.95), LTL: 95.37 (-2.21), KWEB: 37.04 (-0.63), IGM: 101.18 (+0.40), REW: 57.29 (unch), SOXL: 117.85 (+6.44), QQQC: 23.35 (-0.30), FDN: 61.60 (+0.07), FCOM: 27.59 (-0.01), SMH: 52.71 (+0.67), SOXX: 89.18 (+1.71), TECS: 11.43 (-0.15), RYT: 89.30 (+0.63), PSCT: 48.25 (+0.45), SSG: 54.00 (-2.40), FTEC: 31.50 (+0.19), PSJ: 38.96 (+0.07), IGV: 92.05 (+0.26), PSI: 23.57 (+0.51), USD: 86.02 (+3.08), MTK: 99.75 (+0.79), VOX: 89.99 (-0.11), IGN: 35.81 (+0.37), VGT: 104.81 (+0.59)

Biotech Ripe for Correction as Risk of Cyclical Drawdown Looms
at The Street - Mon Nov 10, 2:15PM CST
Look at the performance of the biotechnology sector vs. tech since the 2008 crisis.
XBI: 171.38 (+3.00), XLK: 41.67 (+0.14), IBB: 295.25 (+6.41)

The Best Offense Is A Good Defense
Eric Parnell, CFA - Seeking Alpha - Sat Nov 08, 8:36AM CST
What a difference a few weeks make. Stocks are once again in rally mode and bullishness is back on the street. After bottoming back on October 15, stocks as measured by the S&P 500 Index have rallied an impressive +11.6% to advance to fresh new...
XLB: 49.87 (+0.59), BDX: 130.94 (+1.40), SPLV: 37.14 (+0.15), DAL: 44.79 (+1.36), XLY: 69.33 (+0.13), BBY: 34.90 (-0.39), XLU: 45.66 (+0.13), SO: 47.25 (+0.17), XLV: 68.67 (+1.09), YHOO: 51.75 (-0.62), XLP: 48.26 (+0.18), SPY: 205.55 (+1.18), SPHB: 34.46 (+0.36), XLK: 41.67 (+0.14), PG: 87.95 (+0.11), XLI: 56.65 (+0.42), XLE: 85.83 (+0.07)

The 9 Best Exit Returns In Mobile Internet
Tim Merel - Seeking Alpha - Wed Nov 05, 3:07PM CST
Mobile internet exit activity via trade exits (i.e. M&A) and IPOs rocketed 7x to $94B in the 12 months to Q3 2014, with mobile internet revenue forecast to hit $700B by 2017 , 32 "billion dollar" mobile internet companies now worth...
TECL: 142.12 (+1.69), XLK: 41.67 (+0.14), VGT: 104.81 (+0.59), IYW: 104.57 (+0.55)

Pause For A Cause: A 3-Month Outlook On The S&P 500 And U.S. 10-Year Yield
Cerebro1 - at Seeking Alpha - Wed Nov 05, 2:44PM CST

SPY: 205.55 (+1.18), IEF: 105.10 (+0.12), XLY: 69.33 (+0.13), XLK: 41.67 (+0.14), XLI: 56.65 (+0.42), XLU: 45.66 (+0.13), XLF: 24.14 (+0.08), XLV: 68.67 (+1.09)

A Valuation Snapshot By Sectors
Fred Piard - at Seeking Alpha - Wed Nov 05, 9:09AM CST

XLB: 49.87 (+0.59), XLP: 48.26 (+0.18), XLY: 69.33 (+0.13), XLK: 41.67 (+0.14), XLI: 56.65 (+0.42), XLU: 45.66 (+0.13), XLF: 24.14 (+0.08), XLV: 68.67 (+1.09), XLE: 85.83 (+0.07)

3 Top Ranked ETFs from Hottest Sectors - ETF News And Commentary
Neena Mishra - ZACKS - Tue Nov 04, 11:37AM CST
Most companies in these sectors have reported excellent results for the third quarter.
ITA: 112.45 (+1.35), XLK: 41.67 (+0.14), IYT: 162.22 (+0.51)

Value Investing In An Environment Of Accelerating Technological Change
Victor Wendl - at Seeking Alpha - Mon Nov 03, 10:35PM CST
The director of research at Google (NASDAQ: GOOG ) (NASDAQ: GOOGL ), Ray Kurzweil, wrote a book a number of years ago titled The Singularity . It is a point in the not-too-distant future where the fields of genetics, nanotechnology and robotics...
SPY: 205.55 (+1.18), XLK: 41.67 (+0.14)

Bullish Conviction Returns, But Market Likely To Consolidate Its V-Bottom
Scott Martindale - Seeking Alpha - Mon Oct 27, 7:56AM CDT
Bulls showed renewed backbone last week and drew a line in the sand for the bears, buying with gusto into weakness as I suggested they would. After all, this was the buying opportunity they had been waiting for. As if on cue, the start of the World...
IYK: 104.94 (+0.49), PBE: 49.83 (+0.80), IYJ: 106.98 (+0.67), IYH: 144.25 (+2.40), FB: 74.34 (+0.10), IYM: 86.12 (+0.96), IYC: 131.10 (+0.52), SLG: 114.33 (+1.12), WDC: 100.39 (+1.85), IYF: 88.01 (+0.21), IYE: 48.62 (+0.05), KBWI: 68.30 (unch), IYZ: 30.59 (+0.01), SPY: 205.55 (+1.18), JPM: 60.53 (+0.15), GILD: 103.71 (+3.27), IDU: 114.54 (+0.37), XLK: 41.67 (+0.14), REGN: 413.22 (+13.57), IYW: 104.57 (+0.55)

Biotechs are running circles around internet stocks
Seeking Alpha - at Seeking Alpha - Sun Oct 26, 8:44AM CDT

PXQ: 34.03 (+0.32), ROM: 152.49 (+1.68), TLL: 55.40 (unch), XBI: 171.38 (+3.00), IBB: 295.25 (+6.41), XSW: 93.00 (+0.29), QTEC: 43.24 (+0.33), PBS: 25.05 (+0.13), PTF: 37.25 (+0.53), FXL: 33.68 (+0.38), IYZ: 30.59 (+0.01), TECL: 142.12 (+1.69), BBH: 114.67 (+2.42), XLK: 41.67 (+0.14), TDIV: 27.90 (+0.17), XSD: 73.11 (+1.47), IYW: 104.57 (+0.55), XTL: 57.07 (+0.28), SOXS: 15.97 (-0.95), PBE: 49.83 (+0.80), LTL: 95.37 (-2.21), IGM: 101.18 (+0.40), FBT: 98.57 (+1.78), REW: 57.29 (unch), SOXL: 117.85 (+6.44), FDN: 61.60 (+0.07), FCOM: 27.59 (-0.01), SMH: 52.71 (+0.67), SOXX: 89.18 (+1.71), TECS: 11.43 (-0.15), RYT: 89.30 (+0.63), PSCT: 48.25 (+0.45), SSG: 54.00 (-2.40), FTEC: 31.50 (+0.19), PSJ: 38.96 (+0.07), IGV: 92.05 (+0.26), PSI: 23.57 (+0.51), USD: 86.02 (+3.08), MTK: 99.75 (+0.79), VOX: 89.99 (-0.11), IGN: 35.81 (+0.37), VGT: 104.81 (+0.59)

Are XLK And Its Holdings Overpriced?
Fred Piard - at Seeking Alpha - Sat Oct 25, 11:55PM CDT

T: 35.72 (-0.13), IBM: 161.89 (-2.27), FB: 74.34 (+0.10), XLK: 41.67 (+0.14), GOOGL: 544.51 (-2.13), MSFT: 48.74 (-0.72), INTC: 34.71 (+0.47), VZ: 51.22 (-0.18), GOOG: 535.03 (-1.48), AAPL: 115.47 (+1.48), CSCO: 26.59 (+0.12)

The Obscure Economic Idea Behind SaaS Pricing Challenges
Tomasz Tunguz - Seeking Alpha - Thu Oct 23, 3:10PM CDT
(click to enlarge) Startups struggle to set the right price for their products because pricing dynamics in the field don't obey the laws taught in the classroom. The standard supply and demand curves, drawn above, imply that as price increases...
XLK: 41.67 (+0.14), ZEN: 24.29 (+0.21)

Qualcomm: Offers Strong Value Buy Opportunity On Current Pullback
Shiraz Lakhi - at Seeking Alpha - Wed Oct 22, 8:09AM CDT

QCOM: 72.01 (+1.61), XLK: 41.67 (+0.14)

Tech ETFs to Benefit Most on Apple's Earnings Beat - ETF News And Commentary
Sweta Killa - ZACKS - Tue Oct 21, 12:00PM CDT
These tech ETFs are poised to outperform in the coming days given Apple's blockbuster Q4 performance.
XLK: 41.67 (+0.14), VGT: 104.81 (+0.59), AAPL: 115.47 (+1.48), IYW: 104.57 (+0.55)

Industrial ETF: No. 8 Select Sector SPDR Over 2014's First 9 Months
J.J. McGrath - at Seeking Alpha - Fri Oct 17, 2:28PM CDT

XLB: 49.87 (+0.59), SPY: 205.55 (+1.18), XLK: 41.67 (+0.14), XLI: 56.65 (+0.42)

Could The S&P 500 Fall To 1,625?
Chris Ciovacco - at Seeking Alpha - Wed Oct 15, 8:37PM CDT
A Trip Down Correction Memory Lane Since the correction-less market theory has been dropping transmission parts over the last three weeks, it is prudent to revisit some topics we have touched on in the past. We will focus on two questions: How...
SPY: 205.55 (+1.18), XLK: 41.67 (+0.14), TLT: 119.52 (+0.33)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Firefox Champions Privacy with Iconic Internet Campaign

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

CapCut's Role in AI-Assisted Small Biz Marketing

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...